VJNeurology is committed to improving our service to you

Share this video  

VJNeurology is committed to improving our service to you

AAN 2022 | Cenobamate for focal seizures: longer-term efficacy and adverse events

William E. Rosenfeld, MD, FAAN, The Comprehensive Epilepsy Care Center for Children and Adults, St Louis, MO, discusses recent data looking at the longer-term safety and efficacy of cenobamate. Cenobamate is a new antiseizure medication, indicated for the treatment of focal onset seizures in adults without adequate seizure control on at least 2 prior medications. A wealth of data supporting the safety and efficacy of the breakthrough therapy has accumulated in recent years, including randomized controlled trials that fueled its approval and several post-hoc analyses. These studies have shown that cenobamate use enables rapid and sustained seizure control, with a low incidence of cognitive and psychiatric adverse events. This interview took place at the American Academy of Neurology 2022 Congress in Seattle, WA.